Author

Marianne Bach Treppendahl

Observed names: M B Treppendahl, M. B. Treppendahl, M. Bach Treppendahl, M. Treppendahl, M.B. Treppendahl, MARIANNE TREPPENDAHL, Marianne B. Treppendahl, Marianne Treppendahl, Treppendahl, Marianne Bach

Institutions: University of Copenhagen, Mayo Clinic, University of Leicester, Novo Nordisk (Denmark), University of Manchester, NIHR Leicester Biomedical Research Centre, University of Missouri–Kansas City, University of Glasgow

Observed institutions: University of Copenhagen, Mayo Clinic, University of Leicester, Novo Nordisk (Denmark), Copenhagen University Hospital, Gentofte Hospital, Rigshospitalet, University of Manchester, National Institute for Health and Care Research, NIHR Leicester Biomedical Research Centre, University of Missouri–Kansas City, University of Glasgow

OpenAlex ID: A5048183455

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

2023 · Mikhail N. Kosiborod, Steen Z. Abildstrøm, et al. · New England Journal of Medicine · 1,649

PDF

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

2024 · Mikhail N. Kosiborod, Mark C. Petrie, et al. · New England Journal of Medicine · 748

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

2019 · Helena W. Rodbard, Julio Rosenstock, et al. · Diabetes Care · 461

PDF

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

2020 · Mansoor Husain, Stephen C. Bain, et al. · Diabetes Obesity and Metabolism · 209

PDF

Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

2015 · Andreas D. Ørskov, Marianne B. Treppendahl, et al. · Oncotarget · 188

PDF

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

2011 · Marianne Bach Treppendahl, Xiangning Qiu, et al. · Blood · 115

PDF

Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers

2020 · Sunil Kumar Saini, Andreas Due Ørskov, et al. · Nature Communications · 101

PDF

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype

2023 · Mikhail N. Kosiborod, Steen Z. Abildstrøm, et al. · JACC Heart Failure · 97

Predicting response to epigenetic therapy

2014 · Marianne B. Treppendahl, Lasse S. Kristensen, et al. · Journal of Clinical Investigation · 97

PDF

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies

2014 · A O Gang, T M Frøsig, et al. · Blood Cancer Journal · 86

PDF

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

2011 · L. Mollgard, L. Saft, et al. · Haematologica · 51

PDF

Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table

2023 · Francesco Cosentino, Subodh Verma, et al. · European Heart Journal · 48

PDF

Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes

2016 · Jakob Werner Hansen, Maj Karoline Westman, et al. · American Journal of Hematology · 40

PDF

Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing

2013 · Lasse Sommer Kristensen, Marianne Bach Treppendahl, et al. · Scientific Reports · 34

PDF

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)

2018 · Steven P. Marso, Michael A. Nauck, et al. · The American Journal of Cardiology · 32

PDF

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial

2018 · Michael A Nauck, Karen Tornøe, et al. · Diabetes and Vascular Disease Research · 31

Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations

2016 · Derya Aslan, Christian Garde, et al. · Oncotarget · 31

Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients

2015 · Alexandra Helbo, Marianne Treppendahl, et al. · Genes · 26

PDF

Diffuse large B-cell lymphoma with combinedTP53mutation andMIR34Amethylation: Another “double hit” lymphoma with very poor outcome?

2014 · Fazila Asmar, Christoffer Hother, et al. · Oncotarget · 26

PDF

Epigenetic Changes in Cancer as Potential Targets for Prophylaxis and Maintenance Therapy

2008 · Kirsten Grønbæk, Marianne Treppendahl, et al. · Basic & Clinical Pharmacology & Toxicology · 25

PDF

A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies

2012 · K. Gronbaek, C. Muller-Tidow, et al. · Haematologica · 24

PDF

Chronic Idiopathic Thrombocytopenic Purpura

1995 · Marianne Bach Treppendahl, Ove Juul Nielsen · New England Journal of Medicine · 19

Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC 5 in MDS and AML with deletion 5q

2012 · Marianne B. Treppendahl, Lars Möllgård, et al. · European Journal Of Haematology · 18

Analysis of Epigenetic Modifications of DNA in Human Cells

2013 · Lasse Sommer Kristensen, Marianne Bach Treppendahl, et al. · Current Protocols in Human Genetics · 16

54-OR: Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2

2019 · EDUARD MONTANYA, JULIO ROSENSTOCK, et al. · Diabetes · 9

Works count: 50

Citation count: 4,197

H-index: 21

I10-index: 24